Squamous cell carcinoma - I-Squamous Cell Carcinoma
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Squamous cell carcinoma well differentiated ― Iactinic keratosis esecaleni iyabonwa.
References
Squamous cell carcinoma (SCC) ngowesibini umhlaza wolusu uxhaphakileyo eMelika, emva kwe basal cell carcinoma. Iqhele ukuqala kwizilonda ezingaphambi komhlaza ezibizwa ngokuba yi actinic keratosis , kwaye zinokusasazeka kwamanye amalungu omzimba. Oyena nobangela kukukhuseleka kwimitha ye-ultraviolet (UV) evela elangeni, ethi iqokelele ngokuhamba kwexesha. Unyango ludla ngokubandakanya ukususwa ngotyando, ngakumbi kwi-SCC entloko nasentanyeni. Unyango ngemitha lukhetho lwezigulana ezindala okanye abo bangakwaziyo ukwenza utyando. I-Immunosuppression yonyusa umngcipheko we-SCC. Nangona kunqabile, i-SCC inokusasazeka, ngakumbi kwizigulane ezine-immune system ezibuthathaka. Ukuhlolwa rhoqo kunye nokukhuselwa elangeni kubalulekile kwabo bane-SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) ngumhlaza wesibini oxhaphakileyo ebantwini, kwaye amanani awo ayenyuka. Nangona i-CSCC ihlala ibonisa ukuziphatha kakuhle kweklinikhi, inokusasazeka kwindawo kunye nakwezinye iindawo zomzimba. Iingcali zenzululwazi zichonge iindlela ezithile ezibandakanyekayo kuphuhliso lwe-CSCC, olukhokelela kunyango olutsha. Inani eliphezulu leenguqu kunye nomngcipheko onyukileyo kwizigulane ezikhuselweyo ziye zakhuthaza ukuphuhliswa kwe-immunotherapy. Olu phononongo lujonga iingcambu zofuzo ze-CSCC kunye nonyango lwamva nje olujolise kwiimolekyuli ezithile kunye ne-immune system.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Uxilongo kunye noNyango
#Dermoscopy
#Skin biopsy